Title : Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?

Pub. Date : 2020 Nov

PMID : 32833070






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 RESULTS: Most notably, patients with BRCA1/2 mutant ovarian cancer benefit from maintenance treatment with PARP inhibitors after (complete or partial) response to platinum-based chemotherapy. Platinum collagen type XI alpha 2 chain Homo sapiens